• In the late s Solvay Pharmaceuticals discontinued

  2025-02-24

  

  In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the

• Our published data showed that in mouse

  2025-02-21

  

  Our published data showed that, in mouse heart, the protein level of WDR1 was highest during the embryonic stage, but became progressively decreased to a constant level from birth to adulthood (Yuan et al., 2014), indicating an important role of WDR1 in embryonic heart development. However, function

• Altogether the situations described above clearly impede the

  2025-02-21

  

  Altogether, the situations described above clearly impede the critical steps of drug discovery and development and the scientific process in general [14]. In conclusion, it is the opinion of these authors that many exciting lines of drug discovery (which includes those devoted to nAChR ligands) have

• The anorexic effect observed when AR

  2025-02-21

  

  The anorexic effect observed when AR231630 is infused into the VTA could be the result of the DA release inhibition, as previously described [11]. However, there is also a hedonic aspect in feeding that possibly involves dopaminergic mechanisms of reward. Helm et al. showed a functional link between

• Further analysis sought to understand the mechanism associat

  2025-02-21

  

  Further analysis sought to understand the mechanism associated with the autotaxin-mediated increase of miR-489-3p in circulation. Based upon sequence complementarity, DIANA TarBase predicted miR-489-3p targets MAPK2K1, or MEK1, an oncogene widely dysregulated in cancer (Fig. 4A). To test this relati

• Inactivation of autophagy can also impact the surface intern

  2025-02-21

  

  Inactivation of autophagy can also impact the surface internalization of MHC I molecules, leading to increased antigen presentation. Inactivation of autophagy factors Atg5 and Atg7 in DCs causes elevation of MHC I surface levels by decreasing endocytosis due to a poor recruitment of adaptor-associat

• ATM is generally regarded to be the principal

  2025-02-21

  

  ATM is generally regarded to be the principal mediator of the G1 Anti-tumor natural product checkpoint, whereas the induction of the intra-S-phase and G2/M checkpoints are usually primarily related to ATR function. However, several studies have demonstrated that, depending on the cellular context an

• Estrogen exerts its genomic action via estrogen nuclear rece

  2025-02-21

  

  Estrogen exerts its genomic action via Cyanidin-3-O-glucoside chloride antioxidant nuclear receptor: ERα and ERβ. The distribution of ERα and/or ERβ positive neurons in CNS of different species has been mapped extensively by various methods [41], [42], [43], [44], [45], [46], [47], [48], [49], [50]

• In summary these data show that agonist exposure induces

  2025-02-21

  

  In summary, these data show that agonist exposure induces internalization and reduction in cell surface HA-mAPJ expression that occurs relatively rapidly during agonist exposure and recovers more slowly after agonist removal. Moreover the ppERK response of mAPJ-HEK293 cells to [Pyr1]apelin-13 desens

• PF is orally bioavailable and

  2025-02-21

  

  PF-06409577 is orally bioavailable and has appropriate pharmacokinetic properties for use in rodents, allowing us to evaluate its impact on lipid and cholesterol biosynthesis in vivo (Cameron et al., 2016). PF-06409577 lowered the incorporation of 14C-acetate into hepatic lipids in vivo in a dose de

• Since HETEs and lipoxins the downstream products of LOX from

  2025-02-20

  

  Since HETEs and lipoxins, the downstream products of 12/15-LOX from AA, may alter cellular proliferation and apoptosis,31, 32 and possibly explain the increase of tumour progression and metastasis. However, we here found that HETEs did not affect the proliferation of melanoma in vitro. This may part

• br Discussion To our knowledge this

  2025-02-20

  

  Discussion To our knowledge, this is the first case report that demonstrates the presence of a novel T1151K ALK mutation in a patient with disease progression after crizotinib and then ceritinib. As early as 2011, Zhang et al. identified T1151K among other resistance mutations to crizotinib in Ba

• It was also shown that of crizotinib resistance mechanisms c

  2025-02-20

  

  It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation

• mcpa property search br AHR expression in cancer Perhaps the

  2025-02-20

  

  AHR expression in cancer Perhaps the earliest indicator that the AHR might play an ongoing role in tumorigenesis, independent of its role in generating mutations, was the demonstration that non-genotoxic 2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD) is a carcinogen in animals and humans [7]. Althoug

• Adiponectin also works on AdipoR

  2025-02-20

  

  Adiponectin also works on AdipoR1, inducing extracellular Ca2+ influx necessary for activation of Ca2+/calmodulin-dependent protein kinase kinase (CaMKK)β, AMPK (Fig. 1). This step is then followed by activation of SirT1 and increased expression and decreased acetylation of PPARγ coactivator (PGC)-1

14708 records 1/981 page Next 12345 下5页 Last page